AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

RA'ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), an innovative medical technology company valued at $15.7 million, has announced positive initial results from its collaboration ...

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously ...

Lucky for you, the best Presidents' Day mattress sales include affordable options from popular mail-order company Tuft & ...

MiscellaneousBIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CESTBasel, Switzerland. February 11, 2025, 7am CET  BV500 reaches ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Developed by CSIR’s National Institute for Interdisciplinary Science and Technology (NIIST), the "Sṝrjanam" rig represents a ...

The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients ...